RxDoctor Payments Data

Casey Neuman

Nurse Practitioner · Wausau, WINPI 1184226805

Payments from drug & device makers

$453in general payments, 2019–2025

Across 20 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • 180 Medical, Inc.$136
  • Teleflex LLC$120
  • AbbVie$60
  • AstraZeneca$35
  • Coloplast$34
  • Sumitomo Pharma America, Inc.$28
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$41892%
  • Education$358%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
180 Medical, Inc.5$136
Teleflex LLC7$120
AbbVie3$60
AstraZeneca1$35
Coloplast1$34
Sumitomo Pharma America, Inc.1$28
Medtronic1$24
Astellas Pharma US Inc1$17

How this compares

$453 in reported general payments places this provider in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$55,378
Medicare patients
434
Services billed
1,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron116$65,855
GemtesaVibegron110$64,720
Tamsulosin Hcl495$7,055
Oxybutynin Chloride ErOxybutynin Chloride158$3,321
Finasteride232$2,966
Methenamine Hippurate29$1,845
Fosfomycin Tromethamine17$1,432
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$1,042
Testosterone Cypionate14$788
Potassium Citrate ErPotassium Citrate14$740
Cefdinir40$601
Oxybutynin Chloride25$552
Doxazosin Mesylate35$508
Dutasteride20$507
Solifenacin Succinate12$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$17$65,855116 claims
Sumitomo Pharma America, Inc.Gemtesa$28$64,720110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →